| 1 |
35084694 | Comparison of the Efficacy and Safety of Bexarotene and Photo(Chemo)Therapy Combination Therapy and Bexarotene Monotherapy for Cutaneous T-Cell Lymphoma. | 2022 Mar |
1 |
| 2 |
35221968 | Quantitative Analysis of Immune-Reactive Cells among Leukocytes Is Useful for the Diagnosis of Drug Eruptions Caused by Bexarotene. | 2022 Jan-Apr |
2 |
| 3 |
32207181 | Case series of cutaneous T-cell lymphomas treated with bexarotene-based therapy. | 2020 Jun |
4 |
| 4 |
30903705 | Bexarotene-induced hypothyroidism: Characteristics and therapeutic strategies. | 2019 Jul |
2 |
| 5 |
29521139 | Emerging roles of bexarotene in the prevention, treatment and anti-drug resistance of cancers. | 2018 May |
1 |
| 6 |
29704526 | A novel gene expression analytics-based approach to structure aided design of rexinoids for development as next-generation cancer therapeutics. | 2018 Jul |
1 |
| 7 |
30294626 | Dataset on the response of Hut78 cells to novel rexinoids. | 2018 Oct |
1 |
| 8 |
30422238 | Association of APOA5 and APOC3 Genetic Polymorphisms With Severity of Hypertriglyceridemia in Patients With Cutaneous T-Cell Lymphoma Treated With Bexarotene. | 2018 Dec 1 |
3 |
| 9 |
28319634 | Late-onset bexarotene-induced CD4 lymphopenia in a cutaneous T-cell lymphoma patient. | 2017 Feb |
2 |
| 10 |
28748653 | Oral bexarotene for post-transplant cutaneous T-cell lymphoma. | 2017 Sep |
2 |
| 11 |
24732904 | Polish Lymphoma Research Group Experience With Bexarotene in the Treatment of Cutaneous T-Cell Lymphoma. | 2016 May-Jun |
2 |
| 12 |
26332008 | Woringer-Kolopp (Pagetoid Reticulosis) disease successful response to bexarotene gel. | 2016 Jan-Feb |
1 |
| 13 |
26811014 | Panoptic clinical review of the current and future treatment of relapsed/refractory T-cell lymphomas: Cutaneous T-cell lymphomas. | 2016 Mar |
1 |
| 14 |
25826424 | Retinoids Bias Integrin Expression and Function in Cutaneous T-Cell Lymphoma. | 2015 Aug |
1 |
| 15 |
26012882 | Modulation of Retinoic Acid Receptor Subtypes by 5- and 8-Substituted (Naphthalen-2-yl)-based Arotinoids. | 2015 Aug |
1 |
| 16 |
26451138 | Identification of Bexarotene as a PPARγ Antagonist with HDX. | 2015 |
1 |
| 17 |
26687705 | Marked lowering of high-density lipoprotein cholesterol levels due to high dose bexarotene therapy. | 2015 Nov-Dec |
2 |
| 18 |
23968145 | A case of idiopathic follicular mucinosis treated with bexarotene gel. | 2014 Jul |
1 |
| 19 |
24285015 | Final results of phase II trial of doxorubicin HCl liposome injection followed by bexarotene in advanced cutaneous T-cell lymphoma. | 2014 Jan |
2 |
| 20 |
22917895 | Acitretin for the treatment of cutaneous T-cell lymphoma. | 2013 Feb |
1 |
| 21 |
22963233 | U.K. consensus statement on safe clinical prescribing of bexarotene for patients with cutaneous T-cell lymphoma. | 2013 Jan |
1 |
| 22 |
23557425 | Role of bexarotene in the treatment of cutaneous T-cell lymphoma: the clinical and immunological sides. | 2013 Apr |
1 |
| 23 |
23837676 | Bexarotene in cutaneous T-cell lymphoma: third retrospective study of long-term cohort and review of the literature. | 2013 Sep |
5 |
| 24 |
24136145 | Phase II study of gemcitabine and bexarotene (GEMBEX) in the treatment of cutaneous T-cell lymphoma. | 2013 Nov 12 |
1 |
| 25 |
24278042 | Oral retinoids and rexinoids in cutaneous T-cell lymphomas. | 2013 Feb |
1 |
| 26 |
22678563 | Ten-year experience of bexarotene therapy for cutaneous T-cell lymphoma in Finland. | 2012 May |
2 |
| 27 |
23149703 | Combination treatment in CTCL: the current role of bexarotene. | 2012 Dec |
1 |
| 28 |
21461579 | Confirmation of the biological significance of transthyretin as a biomarker for cutaneous T-cell lymphoma by its protein interaction partners. | 2011 Jan-Feb |
1 |
| 29 |
21547336 | Molecular markers associated with clinical response to bexarotene therapy in cutaneous T-cell lymphoma. | 2011 Sep |
3 |
| 30 |
19845753 | About the cutaneous targets of bexarotene in CTCL patients. | 2010 Aug |
2 |
| 31 |
19845755 | Absence of modulation of CD4+CD25 regulatory T cells in CTCL patients treated with bexarotene. | 2010 Aug |
2 |
| 32 |
20484880 | Evolution of clinical and molecular responses to bexarotene treatment in cutaneous T-cell lymphoma. | 2010 |
2 |
| 33 |
19016373 | Evaluation of the efficacy of the combination of oral bexarotene and methotrexate for the treatment of early stage treatment-refractory cutaneous T-cell lymphoma. | 2009 |
4 |
| 34 |
19222457 | Bexarotene therapy for mycosis fungoides and Sézary syndrome. | 2009 Jun |
3 |
| 35 |
18405187 | Bexarotene monotherapy for epidermotropic CD8+ CTCL. | 2008 Jan |
1 |
| 36 |
18559673 | Clinical and in vitro resistance to bexarotene in adult T-cell leukemia: loss of RXR-alpha receptor. | 2008 Sep 15 |
2 |
| 37 |
18615708 | CD8+ cutaneous T-cell lymphoma successfully treated with bexarotene: a case report and review of the literature. | 2008 Sep |
2 |
| 38 |
17366595 | Results of a phase II trial of oral bexarotene (Targretin) combined with interferon alfa-2b (Intron-A) for patients with cutaneous T-cell lymphoma. | 2007 May 1 |
1 |
| 39 |
17474355 | Choices in the treatment of cutaneous T-cell lymphoma. | 2007 Feb |
2 |
| 40 |
17553039 | The optimal use of bexarotene in cutaneous T-cell lymphoma. | 2007 Sep |
6 |
| 41 |
17763605 | A brief primer on treatments of cutaneous T cell lymphoma, newly approved or late in development. | 2007 Jul |
1 |
| 42 |
16734503 | Management of refractory early-stage cutaneous T-cell lymphoma. | 2006 |
3 |
| 43 |
16844539 | Bexarotene and systemic disease progression in CTCL? | 2006 Aug |
1 |
| 44 |
16882161 | Minimizing adverse side-effects of oral bexarotene in cutaneous T-cell lymphoma: an expert opinion. | 2006 Aug |
2 |
| 45 |
17014481 | Treatment of cutaneous T-cell lymphoma with retinoids. | 2006 Sep-Oct |
2 |
| 46 |
15663654 | Oral bexarotene in a therapy-resistant Sézary syndrome patient: observations on Sézary cell compartmentalization. | 2005 Jan |
2 |
| 47 |
15948982 | Lack of apoptosis of Sézary cells in the circulation following oral bexarotene therapy. | 2005 Jun |
1 |
| 48 |
14988678 | Low-dose oral bexarotene in combination with low-dose interferon alfa in the treatment of cutaneous T-cell lymphoma: clinical synergism and possible immunologic mechanisms. | 2004 Mar |
2 |
| 49 |
15389192 | Cutaneous T-cell lymphoma treatment using bexarotene and PUVA: a case series. | 2004 Oct |
3 |
| 50 |
12852367 | Bexarotene gel: a new skin-directed treatment option for cutaneous T-cell lymphomas. | 2003 Apr |
2 |